NCT00462982View on ClinicalTrials.gov

Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Kidney CancerMelanoma (Skin)Metastatic Cancer
Interventions
DRUG

sunitinib malate

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00462982 - Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma | Biotech Hunter | Biotech Hunter